Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 07, 2021 11:12am
124 Views
Post# 33152186

RE:RE:As usual

RE:RE:As usual I doubt that the Quebec pension plan you are referring to is selling - they already have reduced their position a lot and they likely need to keep some TH for appearances sake. But they evidently did not want to participate in the offering because they had lost faith in the company, which is understandable given its performance relative to almost all other stocks. 

They will likely be buyers again at higher prices if either the NASH or cancer trials (or both) cause the stock to finally start moving higher. 

Wino115 wrote: Dubuc should try to round-up an institutional buying group to take on a large trade from the Canadian instutions that view the pipeline as too risky and are likely the ones who keep dripping on it every day.  They have a chunk, and he should find buyers for that chunk and be done with it. Do it at a 10% discount to market and let's move on with investors that "get it". 

Bucknelly21 wrote: Thtx is the only thing red in a sea of green.... 




<< Previous
Bullboard Posts
Next >>